An Introduction to Stroke
Most strokes (85%) are caused by acute ischaemia due to blockage of a cerebral artery, leading to loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral or subarachnoid haemorrhage. Treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytics and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. Increasingly, oral anticoagulants are preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia (e.g. transplantation of mesenchymal stem cells) are also emerging as potentially useful.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Hans Christoph Diener – PFO Closure: Addressing the Unmet Need for Reducing Ischemic Stroke Risk
Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany), talks to us around the highlights of his recently published co-authored review article entitled: Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke, freely available to access here. Questions 1. What is […]
Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke
US Neurology. 2020;16(1):54–60 DOI: https://doi.org/10.17925/USN.2020.16.1.54
Globally, a high proportion (around 25%) of transient ischemic attacks (TIAs) and ischemic strokes are cryptogenic.1,2 The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification defines a cryptogenic stroke as a brain infarction that is not caused by definite cardioembolism, large artery atherosclerosis, or small artery disease, despite extensive investigations.3 The “ASCOD” classification defines strokes […]
Anna Tancin Lambert, EAN 2020 – Atrial Fibrillation and Cryptogenic Stroke in the NOR-FIB Study
Anna Tancin Lambert (University of Oslo and Department of Neurology Østfold Hospital Trust, Norway) discussed with us exciting interim findings from the international, multicentre, prospective, observational Nordic Atrial Fibrillation and Stroke (NOR-FIB) study, which highlight atrial fibrillation as the hidden cause of cryptogenic stroke (ClinicalTrials.gov Identifier: NCT02937077). Questions 1. What proportion of stroke and transient […]
Acute Stroke Imaging in the Era of the DAWN, DEFUSE 3 and WAKE-UP Study Findings
European Neurological Review. 2019:14(1):24–7. DOI: https://doi.org/10.17925/ENR.2019.14.1.24
In 2018, two randomised controlled trials, DAWN (the Clinical Mismatch in the Triage of Wake up and Late Presenting Strokes Undergoing Neurointervention with Trevo Thrombectomy Procedure) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischaemic Stroke 3), implemented computed tomography (CT) and magnetic resonance imaging (MRI) in patients with stroke.1,2 These studies showed the […]
Charles Bonnet Syndrome as a Rare Complication in an Ischaemic Stroke
European Neurological Review. 2018;13(2):120–2 DOI: https://doi.org/10.17925/ENR.2018.13.2.120
Charles Bonnet syndrome (CBS) is characterised by the presence of visual hallucinations (VH) and visual sensory deprivation in individuals with preserved cognitive status and without a history of psychiatric illness.1 CBS is a rare, underdiagnosed and under-recognised syndrome, which was first described in 1769 by Charles Bonnet, who observed this phenomenon in his grandfather.1 The […]
Latest Advances in the Treatment of Acute Stroke
US Neurology. 2018;14(2):80–1 DOI: https://doi.org/10.17925/USN.2018.14.2.80
About 85% of strokes are ischemic, and the most severe ischemic strokes are caused by large vessel occlusion due to either artery-to-artery embolism or cardiac embolism. Early treatment is essential to rescue potentially salvageable tissue.1 Until recently, the only proven treatment for acute ischemic stroke was intravenous thrombolysis with recombinant tissue-type plasminogen activator (tPA). […]
Foreword – US Neurology. 2018;14(2):65
US Neurology. 2018;14(2):65
Welcome to the fall edition of US Neurology. This edition features a wide range of articles that provide an opportunity to review developments in the changing treatment landscape for neurological disorders and share expert opinions that should be of interest both to neurologists and the wider medical community. Our expert interviews continue to be […]
Homocysteine Lowering with B Vitamins for Stroke Prevention—A History
US Neurology. 2018;14(1):35–39 DOI: https://doi.org/10.17925/USN.2018.14.1.35
Despite substantial evidence to the contrary, there is still a widespread belief that B vitamins to lower plasma total homocysteine (tHcy) do not prevent stroke. This belief is based on the failure of early clinical trials to show a reduction of stroke with B vitamin therapy. However, it is increasingly clear that harm from cyanocobalamin […]
Ulrich Dirnagl, EAN 2019 – Charles Edouard Brown-Séquard Lecture
The Charles Edouard Brown-Séquard Lecture at EAN 2019 was delivered by Prof. Ulrich Dirnagl, who had a chat with EAN eCommunciations Board Co-Chair, PD DR. Tim von Oertzen about his work. Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN 2019).
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!